ADVANCED VASCULAR THERAPIES, INC.

Medtech · Private

Smart pneumatic compression device for treating critical limb ischemia and peripheral arterial disease

Grants
$750K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Agriculture · Novel Pneumatic Compression Device For Cli$99,716
Federal grantDepartment of Agriculture · Project Summarycritical Limb Ischemia (cli), The Most Severe Form Of Peripheral Arterial Disease (pad) Occurs When Arterial Circulation Is Insufficient To Support The Metabolic Demands Of The Tissue. Amputation Is Often The Result. In Many Diabetic Patients, The Arterial Disease Is So Diffuse And Distal That Revascularization Success Rates Are Low. Mortality Rates For Cli Patients Are High, At 50% Within 5 Years And 85% Within 10 Years. Given The Obesity Epidemic Associated With Diabetes, Develo$649,995
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
676ALAN PENN AND ASSOCIATES, INC.——
677INTEGRATED SENSING SYSTEMS, INC. (ISSYS)——
678LumiraDx Ltd—$682M
679ADVANCED VASCULAR THERAPIES, INC.——
680STARK STREET MATERIALS COMPANY——
681BIOGRAFT, INC.——
682ZIMMER BIOMET HOLDINGS, INC.—$216M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.